NCT04480424
Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)
Registry record
- Lead sponsor
- Grifols Therapeutics LLC
- Conditions
- COVID-19
- Primary completion
- Aug 25, 2021Actual
- Completion
- Locked
- Start
- Locked
- Enrollment
- Locked
- Interventions
- Locked
- Study type
- Locked
- Results on the registry
- Locked
- Record last updated
- Locked
Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerRecorded changes
0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.
Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.